Show simple item record

dc.contributor.author
Russkamp, Norman F.
dc.contributor.author
Myburgh, Renier
dc.contributor.author
Kiefer, Jonathan D.
dc.contributor.author
Neri, Dario
dc.contributor.author
Manz, Markus G.
dc.date.accessioned
2021-03-02T08:47:34Z
dc.date.available
2021-03-02T03:54:56Z
dc.date.available
2021-03-02T08:47:34Z
dc.date.issued
2021-03
dc.identifier.other
10.1016/j.exphem.2021.01.003
en_US
dc.identifier.uri
http://hdl.handle.net/20.500.11850/472326
dc.identifier.doi
10.3929/ethz-b-000472326
dc.description.abstract
Precise replacement of diseased or dysfunctional organs is the goal of regenerative medicine and has appeared to be a distant goal for a long time. In the field of hematopoietic stem cell transplantation, this goal is now becoming tangible as gene-editing technologies and novel conditioning agents are entering the clinical arena. Targeted immunologic depletion of hematopoietic stem cells (HSCs), which are at the very root of the hematopoietic system, will enable more selective and potentially more effective hematopoietic stem cell transplantation in patients with hematological diseases. In contrast to current conditioning regimes based on ionizing radiation and chemotherapy, immunologic conditioning will spare mature hematopoietic cells and cause substantially less inflammation and unspecific collateral damage to other organs. Biological agents that target the stem cell antigen CD117 are the frontrunners for this purpose and have exhibited preclinical activity in depletion of healthy HSCs. The value of anti-CD117 antibodies as conditioning agents is currently being evaluated in early clinical trials. Whereas mild, antibody-based immunologic conditioning concepts might be appropriate for benign hematological disorders in which incomplete replacement of diseased cells is sufficient, higher efficacy will be required for treatment and elimination of hematologic stem cell malignancies such as acute myeloid leukemia and myelodysplastic syndrome. Antibody–drug conjugates, bispecific T-cell engaging and activating antibodies (TEAs), or chimeric antigen receptor (CAR) T cells might offer increased efficacy compared with naked antibodies and yet higher tolerability and safety compared with current genotoxic conditioning approaches. Here, we summarize the current state regarding immunologic conditioning concepts for the treatment of HSC disorders and outline potential future developments. © 2021 ISEH – Society for Hematology and Stem Cells
en_US
dc.format
application/pdf
en_US
dc.language.iso
en
en_US
dc.publisher
Elsevier
en_US
dc.rights.uri
http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.title
Anti-CD117 immunotherapy to eliminate hematopoietic and leukemia stem cells
en_US
dc.type
Journal Article
dc.rights.license
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
dc.date.published
2021-01-20
ethz.journal.title
Experimental Hematology
ethz.journal.volume
95
en_US
ethz.pages.start
31
en_US
ethz.pages.end
45
en_US
ethz.version.deposit
publishedVersion
en_US
ethz.identifier.wos
ethz.identifier.scopus
ethz.publication.place
Amsterdam
en_US
ethz.publication.status
published
en_US
ethz.leitzahl
ETH Zürich::00002 - ETH Zürich::00012 - Lehre und Forschung::00007 - Departemente::02020 - Dep. Chemie und Angewandte Biowiss. / Dep. of Chemistry and Applied Biosc.::02534 - Institut für Pharmazeutische Wiss. / Institute of Pharmaceutical Sciences::03463 - Neri, Dario (ehemalig) / Neri, Dario (former)
ethz.leitzahl.certified
ETH Zürich::00002 - ETH Zürich::00012 - Lehre und Forschung::00007 - Departemente::02020 - Dep. Chemie und Angewandte Biowiss. / Dep. of Chemistry and Applied Biosc.::02534 - Institut für Pharmazeutische Wiss. / Institute of Pharmaceutical Sciences::03463 - Neri, Dario (ehemalig) / Neri, Dario (former)
ethz.date.deposited
2021-03-02T03:55:01Z
ethz.source
SCOPUS
ethz.eth
yes
en_US
ethz.availability
Open access
en_US
ethz.rosetta.installDate
2021-03-02T08:47:45Z
ethz.rosetta.lastUpdated
2022-03-29T05:32:39Z
ethz.rosetta.versionExported
true
ethz.COinS
ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.atitle=Anti-CD117%20immunotherapy%20to%20eliminate%20hematopoietic%20and%20leukemia%20stem%20cells&rft.jtitle=Experimental%20Hematology&rft.date=2021-03&rft.volume=95&rft.spage=31&rft.epage=45&rft.au=Russkamp,%20Norman%20F.&Myburgh,%20Renier&Kiefer,%20Jonathan%20D.&Neri,%20Dario&Manz,%20Markus%20G.&rft.genre=article&rft_id=info:doi/10.1016/j.exphem.2021.01.003&
 Search print copy at ETH Library

Files in this item

Thumbnail

Publication type

Show simple item record